Complete financial analysis of iTeos Therapeutics, Inc. (ITOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iTeos Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wonderful Sky Financial Group Holdings Limited (1260.HK) Income Statement Analysis – Financial Results
- ARMOUR Residential REIT, Inc. (0HHU.L) Income Statement Analysis – Financial Results
- QAD Inc. (QADB) Income Statement Analysis – Financial Results
- EACO Corporation (EACO) Income Statement Analysis – Financial Results
- Drilling Tools International Corp. (DTI) Income Statement Analysis – Financial Results
iTeos Therapeutics, Inc. (ITOS)
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 12.60M | 267.63M | 344.78M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 898.00K | 813.00K | 615.00K | 535.00K | 611.00K | 505.00K |
| Gross Profit | 11.70M | 266.82M | 344.16M | -535.00K | -611.00K | -505.00K |
| Gross Profit Ratio | 92.87% | 99.70% | 99.82% | 0.00% | 0.00% | 0.00% |
| Research & Development | 113.30M | 97.36M | 59.37M | 29.90M | 19.21M | 17.19M |
| General & Administrative | 50.40M | 43.95M | 40.51M | 15.34M | 8.84M | 4.31M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.40M | 43.95M | 40.51M | 15.34M | 8.84M | 4.31M |
| Other Expenses | 0.00 | -3.26M | -10.18M | -5.93M | -4.78M | -163.00K |
| Operating Expenses | 163.70M | 138.04M | 89.69M | 39.31M | 23.27M | 17.82M |
| Cost & Expenses | 163.70M | 138.04M | 89.69M | 39.31M | 23.27M | 17.82M |
| Interest Income | 31.77M | 11.36M | 78.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.00K |
| Depreciation & Amortization | 898.00K | 813.00K | 615.00K | 535.00K | 611.00K | 505.00K |
| EBITDA | -151.10M | 148.38M | 257.08M | -37.84M | -21.72M | -17.48M |
| EBITDA Ratio | -1,199.69% | 48.72% | 74.16% | 0.00% | 0.00% | 0.00% |
| Operating Income | -151.10M | 126.32M | 244.90M | -45.24M | -28.05M | -21.50M |
| Operating Income Ratio | -1,199.69% | 47.20% | 71.03% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 42.07M | 22.41M | 11.56M | 7.15M | 5.71M | 3.46M |
| Income Before Tax | -109.03M | 148.74M | 256.46M | -38.09M | -22.34M | -18.05M |
| Income Before Tax Ratio | -865.66% | 55.58% | 74.39% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.61M | 52.08M | 41.94M | -57.00K | 119.00K | 11.00K |
| Net Income | -112.64M | 96.65M | 214.52M | -38.03M | -22.45M | -18.06M |
| Net Income Ratio | -894.34% | 36.11% | 62.22% | 0.00% | 0.00% | 0.00% |
| EPS | -3.15 | 2.72 | 6.10 | -1.09 | -0.64 | -2.40 |
| EPS Diluted | -3.15 | 2.56 | 5.68 | -1.09 | -0.64 | -2.40 |
| Weighted Avg Shares Out | 35.76M | 35.55M | 35.18M | 35.04M | 35.02M | 7.51M |
| Weighted Avg Shares Out (Dil) | 35.76M | 37.77M | 37.77M | 35.04M | 35.02M | 7.51M |
ITOS Stock Price: Over 40% Increase Pre-Market Details
The stock price of iTeos Therapeutics Inc (NASDAQ: ITOS) increased by over 40% pre-market. These are the details.
iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK
iTeos Therapeutics (NASDAQ: ITOS) and GlaxoSmithKline plc (NYSE: GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody. Under the terms of the collaboration agreement, iTeos will receive an upfront payment of $625 million.
iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
GOSSELIES, Belgium and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics (NASD: ITOS) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential...
iTeos Therapeutics' (ITOS) CEO Michel Detheux on Q1 2021 Results - Earnings Call Transcript
iTeos Therapeutics' (ITOS) CEO Michel Detheux on Q1 2021 Results - Earnings Call Transcript
iTeos Reports First Quarter 2021 Financial Results and Provides Business Update
- Presented differentiated clinical and pharmacodynamic data from Phase 1/2a trial of anti-TIGIT antibody, EOS-448, at AACR 2021; expansion into combination cohorts expected mid-2021 -
iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021
CAMBRIDGE, Mass. and GOSSELIES, Belgium, April 10, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced a presentation featuring...
3 Biotech Stocks With Big Catalysts Around the Corner
Upcoming events could send these stocks screaming higher or lower.
iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
– Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association for Cancer Research Annual Meeting. Company to hold conference call at 8:00 am on April 12 th to discuss results –
iTeos to Present at the 10th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 17, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
Source: https://incomestatements.info
Category: Stock Reports